Sunday 18 October 2026
Export ENTA’s income statement to Excel — free account
Enanta Pharmaceuticals, Inc.
ENTA Healthcare Biotechnology
Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024. In the quarter to June 2026, revenue fell 21.6%, EPS grew 21.2% and free cash flow fell 157.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
11.10
0.37
−3.23%
Follow ENTA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.50 | 5.30 | 6.77 | 3.91 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(42.53) | (51.25) | (38.75) | (39.36) | |
P/B ratio |
4.20 | 3.15 | 3.58 | 3.95 | |
Price to Tangible BV |
4.20 | 3.15 | 3.58 | 3.95 | |
EV/Sales |
3.60 | 2.93 | 3.99 | 1.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.64) | (25.90) | (18.88) | (3.45) | |
EV/FCF |
(6.35) | (21.13) | (14.49) | (2.07) | |
Quick Ratio |
3.62 | 3.70 | 4.35 | 4.03 | |
Current Ratio |
3.76 | 3.84 | 4.44 | 4.21 | |
Net Debt/EBITDA |
11.81 | 15.84 | 18.58 | 10.46 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.22 | 0.22 | 0.20 | 0.20 | |
Operating CF/Net income |
0.51 | 0.55 | 0.98 | 0.35 | |
Capex/Depreciation |
(0.01) | (0.01) | (0.11) | (4.47) | |
Interest Coverage |
(4.17) | (3.57) | (3.65) | (7.70) | |
Research and Development Expense of Revenue |
154.09% | 113.31% | 112.05% | 157.41% | |
Selling, General and Administrative Expense of Revenue |
65.94% | 55.76% | 48.40% | 64.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
25.65% | 21.84% | 20.47% | 26.67% | |
Graham Net Nets |
0.02 | (0.05) | (0.01) | (0.05) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(16.53%) | (20.51%) | (20.29%) | (32.00%) | |
Free Cash Flow Yield |
(8.71%) | (2.62%) | (4.07%) | (12.60%) | |
Revenue per Share |
0.49 | 0.59 | 0.65 | 0.71 | |
Operating CF per Share |
(0.34) | (0.25) | (0.41) | (0.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.07) | |
Free Cash Flow per Share |
(0.34) | (0.25) | (0.41) | (0.37) | |
Cash per Share |
6.51 | 5.64 | 6.46 | 8.85 | |
Shareholders Equity per Share |
3.47 | 4.01 | 4.40 | 3.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.47 | 4.01 | 4.40 | 3.03 | |
Free Cash Flow |
(9.98) | (7.17) | (11.84) | (7.95) | |
Working Capital |
149.45 | 131.97 | 153.96 | 155.78 | |
Capital Expenditures |
(0.01) | (0.01) | (0.14) | (1.46) | |
Net Current Asset Value |
7.82 | (19.70) | (4.23) | (11.68) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.10 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.45 | 24.23 | 24.33 | 22.76 | |
Average Payables |
3.42 | 4.56 | 3.31 | 4.98 | |
Average Assets |
298.95 | 318.85 | 339.07 | 328.69 | |
Average Common Equity |
90.17 | 105.06 | 119.20 | 96.77 |
Columns are period end dates